View of Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry

Return to Article Details Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry Download Download PDF